Shots:

• Dr. Reddy gets exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia & will be responsible for local registrations, marketing, and sales in the licensed territories
• Prestige BioPharma will be responsible for the commercial supply of HD201 from its manufacturing facilities in Osong, South Korea
• Prestige BioPharma’s HD201 (trastuzumab) is a proposed biosimilar to Roche’s Herceptin and can be used for the treatment of HER2 positive breast and metastatic gastric cancer

Ref: Businesswire | Image: Prestige